Quantitative T2* imaging of metastatic human breast cancer to brain in the nude rat at 3 T. by �넚�샇�깮
Quantitative T2* imaging of metastatic human breast cancer to
brain in the nude rat at 3-Tesla:
Quantitative T2* imaging for cellular MRI
Ho-Taek Songa,b,*, Elaine K. Jordana, Bobbi K. Lewisa, Eric Golda, Wei Liua,c, and Joseph
A. Franka,d
aFrank Laboratory, Radiology and Imaging Sciences, Clinical Center, National Institute of Health,
Bethesda, MD, USA
bDepartment of Radiology, College of Medicine, Yonsei University, Seoul, Korea
cPhilips Research North America, Briarcliff Manor, NY, USA
dIntramural Research Program, National Institute of Biomedical Imaging and Bioengineering,
National Institute of Health, Bethesda, MD, USA
Abstract
This study uses quantitative T2* imaging to track ferumoxides-protamine sulfate (FEPro) labeled
MDA-MB-231BRL human breast cancer cells (231BRL) that metastasize to the nude rat brain.
Four cohorts of nude rats were intracardiac (IC) injected with either FEPro labeled, unlabeled,
TRIAL treated (to induce apoptosis) 231BRL cells or saline in order to develop metastatic breast
cancer in the brain. The rat heads were imaged serially over 3-4 weeks using a gradient multi-echo
and turbo spin echo pulse sequences at 3 Tesla with a solenoid receive only 4cm diameter coil.
Quantitative T2* maps of whole brain were obtained by applying single exponential fitting to the
signal intensity of T2* images and the distribution of T2* values in brain voxels were calculated.
MRI findings were correlated with Prussian blue (PB) stain and immunohistochemical stain for
iron in breast cancer and macrophages. Quantiative analysis of T2* from the brain voxels
demonstrated a significant shift to lower values following IC injection of FEPro labeled 231BRL
cells as compared to animals that received unlabeled cells or apoptotic cells or saline. Quartile
analysis based on the T2* distribution obtained from brain voxels demonstrated significant
differences (p<0.0083) in number of voxels with T2* values between 10-35 (Q1), 36-60 (Q2) and
61-86 (Q3) milliseconds from day 1 to 3 weeks post infusion of labeled 231BRL cells compared
to baseline scans. There was no significant differences in the distribution of T2* obtained from
serial MRI in rats receiving unlabeled or TRIAL treated cells or saline. Histological analysis
demonstrated isolated PB positive breast cancer cells scattered in brains of rats that received
labeled cells compared to animals that received unlabeled or apoptotic cells. Quantitative T2*
analysis of FEPro labeled metastasized cancer cells was possible even after the hypointense voxels
are no longer visible on T2*-weighted images.
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INTRODUCTION
Magnetic labeling of cells with superparamagnetic iron oxides (SPIO) particles provides the
ability to monitor the migration of labeled cells into tissues by MRI following direct
implantation or intravenous or arterial infusion (1-18). Single or clusters of magnetically
labeled cells in tissues are usually detected as hypointense voxels on T2 and T2* weighted
images (4,9,11,13,19-21) or hyperintense voxels on “white marker” images (22). As cells
divide the SPIO in the cells are distributed symmetrically or asymmetrically in daughter
cells (23) potentially limiting the ability to visualize transplanted cells in tissues by MRI
(2,24).
Quantifying the numbers of SPIO labeled cells in a voxel on T2* weighted (T2*w) images
from experimental studies is challenging (25). Recently, in vitro (26) and in vivo (27)
visualization of single breast cancer cells labeled with micron sized superparamagnetic iron
oxide nanoparticles (MPIO) at 1.5T has been reported. There are also reports of single stem
cell or immune cell detection using high field strength systems when cells are labeled with
MPIO (28-31) or SPIO nanoparticles (16,27,32,33). However, validation of the number of
magnetically labeled cells within tissues by counting the hypointense voxels is inefficient
and identification of these voxels is dependent on their conspicuity in comparison to signal
intensities (SI) from surrounding parenchyma. Several investigators have suggested that
between 500-1,000 SPIO nanoparticles labeled dendritic cells or stem cells can be detected
as hypointense regions on T2*-weighted images at clinically relevant MRI field strengths
(14,34,35). However, these studies depend on the qualitative evaluation of the images to
detect or delineate the migration of magnetically labeled cells within target tissues or by
double labeling of cells with Indium111 oxine and SPIO, and quantifying the numbers of
labeled cells using single photon emission computerized tomography (14). MR hardware
instability, partial volume effects and or poor signal to noise of T2*-weighted images may
also limit the detection of relatively few numbers of SPIO labeled cells within a voxel (39).
However, quantitative T2* maps derived from multi echo gradient echo pulse sequences
(MGRE) that are not routinely used to determine the presence of iron labeled cells have been
used to quantify small numbers of SPIO labeled cells within tumors (36).
The purpose of this study was to determine the utility of using T2* maps derived from
MGRE pulse sequence to track the dilution of SPIO labeled breast cancer cells over time
that subsequently developed into brain metastases in the nude rat model.
EXPERIMENTAL
Cell Line And Fepro Labeling
The brain seeking metastatic breast cancer cell line MDA-MB-231BR-Luc (231BRL)
(provided by Diane Palmieri, National Cancer Institute NIH) were cultured with DMEM
growth media containing 10% fetal bovine serum and 1 % penicillin streptomycin
antibiotics at 37 C° in a 5% CO2 as previously described (37,38). Culture media and related
supplies were purchased from Gibco® (Invitrogen, Carlsbad, CA). Labeling procedure of
the 231BRL cells with ferumoxides (Feridex IV ®, 11.2 mg/ml, Berlex Laboratories,
Wayne, NJ, USA) contrast agent complexed to preservative free protamine sulfate (10 mg/
ml, American Pharmaceuticals Partner, Schaumburg, IL, USA) followed established
protocol (3). After incubation, trypsinized cells were purified by washing with 10 units/ml
heparinized phosphate buffered saline (PBS) 3 times and filtered through 40μm nylon mesh
(BD Bioscience, Bedford, MA, USA). Cellular viability and proliferation of FEPro labeled
and unlabeled cells were evaluated as previously described by trypan blue exclusion test and
cell proliferation assay using the manufacturer’s standard protocol (3,36).
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FEPro labeled 231BRL cells were incubated overnight with 500 ng/ml of tumor necrosis
factor-related apoptosis inducing ligand (Recombinant Human TRAIL/APO2L, Chemicon
International, Temecula, CA) to determine the effect of dead labeled cells on the T2*
measurements from the brain. Apoptotic cells were determined using the VYBRANT®
apoptosis assay kit #2-Alexa flour 588 annexin V/ propidium iodide (Invitrogen, Carlsbad,
CA) and flow cytometry (FACS Calibur, Becton Dickinson, Franklin Lakes, NJ).
Animal model
All animal studies were approved by the animal care and use committee at the National
Institutes of Health. All animal procedures for producing the metastatic breast cancer in the
brain of nude rats have been previously described (38). In brief, rats were anesthetized with
isoflurane gas and intracardiac (IC) injection of breast cancer cells in heparinized phosphate
buffered saline (PBS) or PBS alone was performed using sterile technique under ultrasound
guidance into the left ventricle (37). For this study, twenty nine 6-7-week-old female nude
rats (Crl:NIH-rnu, Charles River, Wilmington, MA) were divided into 4 groups: Group 1
rats (n=12) received FEPro labeled 231BRL cells; Group 2 rats (n=5) received unlabeled
231BRL cells; Group 3 rats (n=4) were injected 200μl PBS without cells; Group 4 rats (n=4)
received TRAIL treated FEPro labeled 231 BRL cells.
Magnetic Resonance Imaging
MRI scanning of the rat was performed prior to and subsequently on days 1, 2 or 3 and
weekly post IC infusion of 231BRL cells. A 3-Tesla MRI unit (Intera, Philips Medical
System, Netherlands, B.V.) with a solenoid 4 cm receive only coil that is mounted
perpendicular to the main magnetic field (Philips Research Laboratories, Germany) was
used with the following pulse sequences: T2-weighted turbo spin echo (TSE) imaging, TR/
TE = 3200/60 ms, TSE factor = 12, number of average = 8, FOV 50 mm, slice thickness 0.5
mm, matrix 224×256, reconstructed resolution 100×100 μm; T2*-weighted multi-shot echo
planar imaging sequence with blip-off echo planar readout (MEPI) was used for creating
T2* maps with TR/TE = 4560/28 ms, 15 echos, flip angle 30°, number of average = 2, FOV
= 50 mm, slice thickness 0.5 mm, matrix 176×256, reconstructed resolution 200×200 μm.
The MEPI research pulse sequence as used in this study at 3T in order to maximize the use
of the clinical scanner gradients resulting in high resolution images in reasonable scan times.
The conventional multiple gradient echo sequence used for routine clinical MRI studies did
not have the performance features (i.e., echo train length, slice thickness, matrix size and
field of view) required for this study. The total MRI scanning time was approximately 40
minutes per rat.
Pulse chase experiment and iron content measurement
To validate changes in T2* as a result of dilution of SPIO with cancer cell division, a pulse
chase experiment was performed. FEPro labeled and unlabeled 231BRL cells were allowed
to proliferate in culture with media changes every 3 days and were harvested at different
time points (i.e., day 1, 3 and weeks 1, 2, 3 and 4) following initial labeling. FEPro labeled
and unlabeled 231BRL cells were collected centrifuged and 106 cells were resuspended
homogeneously in 1 ml of 1% agar at 60°C and then chilled at 4°C to allow the suspensions
to solidify. Tubes containing cells in agar were kept at 4°C until further study. MRI T2* map
was performed using same scan parameters as in vivo study to determine T2* values.
Prussian blue (PB) stains were preformed on cytospins of harvested cells and iron content on
the samples was performed using NMR relaxometry. FEPro labeled and unlabeled 106 cells
were completely dissolved in 1ml of 5N hydrochloric acid. By using variable-field
relaxometer (Southwest Research Institute, San Antonio, TX) intracellular iron
concentration per cell was determined as previously described (2,4,7).
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Image and statistical analysis
Quantitative T2* maps of the brain were obtained from MEPI images using MEDx image
analysis software (Medical Numerics, Bethesda, MD) fitting the signal (S) intensity of each
voxel from the gradient echo images to a mono-exponential decay as a function of echo
time.
(1)
Region of interests were drawn to extract brain voxels from the T2* maps by an experienced
technologist (B.K.L.). The total number of voxels from the brain was determined and used
to normalize the frequency distribution of the number of voxels with a specific T2* value
using standard spreadsheet software. Normalization allowed for comparison over time and
across subjects and groups. Normalized histograms of the T2* data were used for further
statistical analysis. Only voxels with T2* values between 10-110 milliseconds were used for
this study because less than 0.005% of total brain voxels had a T2* value <10 ms or >110
ms. Quartile (Q) analysis was performed from the T2* normalized histogram by summing
the number of voxels per quartile (i.e., Q1 = 10-35 ms, Q2 = 36-60 ms, Q3 = 61-85 ms, and
Q4 = 66-110 ms). Statistical analysis was performed using standard spreadsheet software
and JMP (version 7.0.1.2 SAS, Cary NC) using descriptive statistics to determine histogram
means and one way analysis of variance to compare different time points among the groups
of animals for each quartile. Statistical significance was based on a one-way analysis of
variance comparing means for all pairs with Tukey-Kramer HSD (39). Statistical significant
p values (<0.05) were calculated with Bonferroni correction for multiple comparisons
Histopathology
Euthanized rats were perfused with heparinzed saline and PBS containing 4 %
paraformaldehyde and 3% sucrose for histological examination. Sliced whole brain in the
MR imaging plane was embedded in paraffin and 6 micron thick sections were obtained.
Deparaffinized slides were stained with Perl’s reagent (PB) for the presence of intracellular
iron (Prussian blue) and counterstained with nuclear fast red as previously described (7).
Consecutive sections were immunohistochemically (IHC) stained with IgG anti-human
cytokeratin antibody (AE1/AE3, DacoCytomation, Denmark) to detect the presence of
human breast cancer, or stained with mouse IgG anti rat CD68 EDX1 antibody (Abcam,
Cambridge, MA) to detect rat macrophages. Deparaffinized slides were hydrated with
graded alcohol series, treated with 3 % H2O2 for 15min to neutralize cellular peroxidase and
then washed with PBS buffer and incubated with Scytek superblock (Scytek Laboratories,
Logan, UT) for 4 min. After blotting excess of serum cytokeratin or CD68 primary antibody
was applied at 4 °C overnight. Slides were treated with HRP conjugated secondary antibody
for 2-3 hours and then the slides stained with ImPACT DAB (3,3′-diaminobenzidine) for
less than 5 min and counterstained with Nuclear Fast Red (Scytek Laboratories, Logan, UT).
PBS buffer washing was done between each step of procedure. Three to five sections were
reviewed from 4 different brain slices from each rat. Histopathology slides were reviewed
and photographed using light microscopy (BX50F, Olympus Optical Co., LTD., Japan) and
the images were processed using Adobe Photoshop 7.0 (San Jose, CA).
RESULTS
Cell labeling
There was no difference in cell viability between FEPro labeled (98.9 ± 0.8 %) and
unlabeled 231BRL cells (99.3 ± 0.8 %) using the trypan blue exclusion assay. In addition,
there was no difference in optical densities of unlabeled (1.25 ± 0.09) and FEPro labeled
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cells (1.18 ± 0.18) measured by MTS cell proliferation assay. Approximately 100% 231
BRL were Prussian blue positive by light microscopy. FACS analysis of TRAIL treated
FEPro labeled 231BRL cells showed that 92.6% of cells were apoptotic and 0.4% cells were
dead. The average iron content for the FEPro labeled 231BRL cells was 14 ± 2.3 pg iron/cell
and TRAIL treated labeled 231BRL cells was 6.7 ± 1.4 pg iron/cell, whereas iron content
for unlabeled 231BRL cells was 0.2 ± 0.1 pg.
In vitro analysis
Figure 1 contains a summary of the pulse chase experiments monitoring the serial dilution of
FEPro in 231BRL cells over 4 weeks by MRI and histology. T2* maps and R2* (1/ T2*)
analysis of label cell phantoms at different time points was performed. T2* maps from the
cell phantom demonstrated an increase in T2* values as tumor cells proliferated with time
that was consistent with the dilution of PB staining (Figure 1B) and iron content (Figure
1D). There was a linear correlation between R2* and iron content in the FEPro labeled
231BRL cells (R2 = 0.976) (Figure 1E). In FEPro labeled 231BRL cells, intracellular iron
contents were as follows: 13.9 ± 3 pg/cell at day 0, 7.2 ± 1.7 pg/cell at day 1, 2.1 ± 0.4 pg/
cells at day 3, with a plateau about 1.3 pg/cell during week 1-4. The iron content of
unlabeled control cells was 0.2 ± 0.1 pg/cell. Histogram plots of the distribution of T2*
values from cell phantoms demonstrate the changes that occur over time as FEPro labeled
cells proliferate and in comparison to unlabeled cells or agarose phantoms (Figure 1F). Box
plot derived demonstrate the mean T2* differences over time from labeled cell phantoms.
The T2* changes that are observed in the labeled cell proliferation study should be used as
an approximation of the T2* changes observed in the Group 1 rats following injection of
labeled cells (Figure 2) since other factors such as metabolism of the SPIO, dilution through
cell division and clearance into the circulation of apoptotic or dead cells would result in a
changes in T2* maps similar to baseline images.
MRI of Brain Metastases
Figure 2 contains serial T2-weighted, calculated T2* map, and T2*-weighted (MEPI TE
20ms) MRIs from a representative Group 1 rat that received 106 FEPro labeled 231 BRL
cells. T2*-weighted images show numerous hypointense voxels with a range of signal
intensities at day 1 that became isointense over time. T2* map demonstrates an apparent
decrease in T2* values at day 1 compared to baseline (red and yellow color in supplemental
material 1, movie) with a shift to higher T2* values over time. Brain metastases were
observed as multiple hyperintense regions on T2-weighted images by week 3 in all animals
that received either labeled or unlabeled cells (Figure 2 and 3). Rats that received IC
injection of TRAIL treated FEPro labeled 231BRL did not develop brain metastases.
Minimal or no changes were observed on T2* maps or T2*-weighted images as compared to
baseline MRIs in rats that were injected with unlabeled (Figure 3) or TRAIL treated
231BRL cells or saline (data not shown).
Quantitative analysis
Figure 4 contains mean normalized histograms of the distribution of T2* values from Group
1 (Figure 4A) and Group 2 (Figure 4B) rats obtained from images acquired at baseline and
serially after injection of breast cancer cells. Rats that received FEPro labeled 231BRL cells
had significantly lower (p<0.0083) T2* values from brain voxels from day 1 through week 3
on histogram plots and quartile analysis as compared to baseline measurements. In
comparison, Group 2 rats did not exhibit changes in the mean T2* measures during the study
evaluation period. Table 1 summarizes the mean T2* values at various time points for the
histograms in Figure 4 from the four groups of rats. T2* histograms and quartile analysis
from rats that received IC injection with FEPro labeled TRAIL treated cells or saline were
unchanged compared to baseline values (supplemental material 2).
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Histopathology
Figure 5 contains the brain sections from a representative Group 1 rat that was euthanized at
week 3. Figure 5A is pre-mortem T2-weighted MRI and Figure 5B is corresponding
hematoxylin and eosin stained section displaying multiple breast cancer metastases. Brain
sections in Figure 5C through 5F were stained either PB for iron or by DAB enhanced IHC
stains for CD68 to detect macrophages. A clear mismatch between PB positive cells and CD
68 positive cells can be detected in hippocampal (Figure 5C) and subcortical (Figure 5D-F)
metastatic lesions. Scattered isolated breast cancer cells near brain metastases were shown to
be cytokeratin and PB positive indicative of dormant or non-dividing labeled cells (Figure
6). There was no evidence of metastatic breast cancer in Group 3 and 4 rats.
DISCUSSION
The major finding of this study was the ability to use quantitative MRI to monitor the
changes in T2* values with time in the rat brain following IC injection of FEPro labeled
brain seeking human breast cancer cell line over time. One day following IC injection of
FEPro labeled cells, multiple hypointense voxels were detected scattered throughout the rat
brain as compared to animals receiving unlabeled or apoptotic cells. Ferumoxides is cleared
from the circulation in the rat within the first 1.5 hours after infusion the SPIO and therefore
FEPro complexes are not responsible for T2* changes observed in the rat brain (40). By
week 1, the hypointense voxels on T2*-weighted images became isointense with the
surrounding brain and qualitative discrimination of between the four groups of rats was no
longer possible. In contrast, analysis of brain T2* values could discriminate between the four
cohorts of animals as well as the serial dilution of FEPro or clearance of labeled 231BRL
cells from the brain with time. Moreover, in vitro analysis of FEPro labeled cells that were
allowed to proliferate demonstrated the shift from lower to higher T2* values with time. The
in vitro phantom results with labeled cells was developed to approximately model the
changes observed in the distribution of T2* values in the rat brain following administration
of labeled cells. However, the in vitro clearance of iron from the breast cancer cells
primarily accounts for serial dilution of the contrast agent and not a decrease in
concentration due to loss by clearance mechanisms of labeled cells from the brain. The
differences in normalized distribution of T2* values and quartile analysis of Group 1 rats
indicates that 3 weeks post infusion of labeled cells would suggest the presence of either
isolated dormant breast cancer cells or higher iron content in the rat brains containing
metastases compared to animals that received unlabeled cells. Histological analysis of brain
sections from Group 1 rats euthanized at 3 weeks revealed rare PB positive tumor cells in
the gray matter and that were not localized in microglia or macrophages.
Immunohistochemical staining of the isolated PB cells were shown to be positive for
cytokeratin indicating that these were breast cancer cells.
MRI tracking of magnetically labeled cells has primarily focused on the ability to visualize
single or clusters of cells as hypointense voxels on T2-weighted, T2*-weighted or balanced
steady state images (16,18,41,42). Alternative approaches have also been developed to
improve the conspicuity of magnetically labeled cells using off-resonance imaging
sequences or post processing techniques to map the local susceptibility gradient from the
echo shifting in k-space (41-46). Mowat et al has recently shown that the threshold to detect
hypointense voxels from SPIO labeled cells was dependent on the intracellular iron and echo
time used to acquire T2*-weighted images (47). There are other reports that suggest the
inability to monitor over time magnetically labeled cells in vivo. Kraitchman et al infused
MSCs labeled with Indium111 oxine and ferumoxides and reported focal and diffuse uptake
of MSC in the area of the myocardial infarction by single photon emission tomography at
day 7 post intravenous injection of cells (48). However, ferumoxides labeled MSCs that
were not detected at 1.5 Tesla were observed on PB staining around the rim of the
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infarction. The authors concluded that MRI has lower sensitivity compared to detect dual
labeled MSC compared to radionuclide approaches. Walczak et al labeled LacZ positive
neural stem cells (NSC) with ferumoxides and monitored the dilution of the contrast agent
over time following intraventricular injection in shi/shi neonate mice (23). NSCs
proliferated and there was dilution of ferumoxides in cells to undetectable levels by two
weeks. Fluorescent microscopy demonstrated LacZ positive NSCs distributed in the
parenchyma that was not correlated to the hypointense region on T2*-weighted images.
These authors stated that based on these results that MRI should only be applied for non-
proliferating (i.e., progenitor or differentiated) cells or for the short term monitoring of cell
undergoing rapid cell division. Quantitative MRI approaches were not used in these studies.
Quantitative MRI techniques have been used to detect invisible pathological processes in
normal appearing white and gray matter that were not apparent using conventional
techniques (49-51). Histogram plots of MR metrics are a global method of displaying
quantitative data and therefore removing location biases associated with attempting to
delineate the extent of invisible pathological process over time. T1, T2 or T2* maps have not
been routinely used to monitor magnetically labeled cells in tissues. Granot et al used 1/T1
(R1) maps to demonstrate the migration of labeled tumor infiltrating fibroblasts into model
of ovarian cancer in mice (52) by monitoring small incremental changes in R1 that
corresponded to areas of labeled cells by confocal microscopy. Quantitative T2* imaging has
also been used to demonstrate the early infiltration of SPIO labeled T-cells sensitized to the
B16 OVA tumor antigen in an adoptive transfer flank tumor model (53).
In the current study, the alteration in T2* values on follow-up studies compared to baseline
allowed for the determination of labeled cells within the rat brain over 3 weeks despite the
breast cancer cell proliferation. The changes in the distribution of brain T2* values over time
may represent the various stages of metastasis formation. Recently, it has been suggested
that the formation of brain metastasis evolves over 4 steps including the initial cancer cell
intravascular arrest, extravasation into the parenchyma, co-option of vessels and peri-
vascular location of cells and angiogenic dependent growth (54). In addition, cancer cells
may die in the vasculature, micro-metastases may regress or individual cells may become
dormant within the parenchyma. The rapid changes in the distribution of brain T2* values
immediately following (i.e., days 1-3) IC infusion of labeled cells would be consistent with
the early clearance of breast cancer cells from the vasculature and the subsequent formation
of metastases from cells that were able to marginate into the parenchyma. The lower T2*
values 3 weeks following infusion of cell may represent the presence of dormant cancer
cells in the brain (36) or low levels of iron in the metastases that are below the detection
threshold by PB staining techniques.
There are several limitations in using MR quantitative maps (e.g., T1, T2, T2*) to monitor
changes in pathology in the brain. As compared to conventional imaging approaches
relaxation time maps usually require off-line image analysis and registration to anatomical
images. In order to obtain reliable and reproducible T2* results more rigorous and stringent
demands on the MRI scanner. Inaccuracies in the MR maps using the clinical scanner from
induced eddy currents, gradient duty cycle and gradient direction, and gradient coil heating
resulting in magnetic field drift, coil design, coil loading and location of sample in the coil
can affect the image quality and reproducibility of quantitative measures (43). Another
limitation of expressing the frequency distribution of T2* values in the brain as normalized
histograms is the loss of spatial localization. However, it is possible to link through software
the measured T2* values from the histogram to locations on the quantitative image maps
(55) thereby providing the ability to identify regional changes over time. Song et al (38) has
previously reported in this model that only 3-5% of all the diffuse hypointense regions
visualized on early post infusion MRI develop into visible breast cancer metastasis therefore
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the early T2* changes can only be used to identify where labeled cells existed but not the
conditions that are suitable for margination resulting in metastases.
In the current study, an analytical approach was used to determine the distribution of FEPro
labeled breast cancer cells in the rat brain from T2* images at 3-Tesla. These results
demonstrate the feasibility of using imaging and quantitative analysis approaches to track
SPIO labeled cells following the intravenous injection to target tissues as part of cell therapy
trials.
Supplementary Material
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231BRL MDA-MB-231BR-Luc
FDA Food and Drug Administration
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IC intracardiac
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Figure 1.
In vitro pulse chase experiment of FEPro labeled 231 BRL cells. (A) Changes in T2* signal
intensities with serial dilution of proliferating SPIO labeled cells. (B) PB stained
micrographs of a period of 4 weeks. Some cells retain SPIO nanoparticles until week 4. (C)
Mean R2* values obtained from T2* map at each time point. (D) Iron content per cell of
each time points. (E) R2* and iron content plot shows linear correlation between R2* value
and iron content in the diluting 231 BRL cells (R2 = 0.976). (F) T2* histograms derived
from T2* map of cell phantoms shows the shifting over time which concordant with the
change of iron contents. (g) Box plot of T2* value shows the distribution of major voxels of
each time point.
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Figure 2.
Serial T2-weighted image (upper), T2* map images (middle), and MEPI T2*-weighted
images at TE 20 from baseline to week 3 following IC injection of FEPro labeled 231BRL
cells. Day 1 T2* map image shows T2* signal changes (red shifted) in the whole rat brain.
T2*-weighted image also shows numerous hypointense voxels (arrowheads) on day 1
images. By week 1 T2* map still shows signal changes to lower T2* values whereas the
T2*w image depicts relatively few hypointense voxels in gray or white matter. T2-weighted
image at week 3 shows multiple metastases (arrowheads).
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Figure 3.
T2-weighted image (upper), T2* map images (middle), and MEPI T2*-weighted images at
TE 20 from baseline to week 3 after intracardiac injection of unlabeled 231BRL cells. No
signal change is observed on MEPI images as compared to baseline. T2-weighted image on
week 3 shows multiple metastatic lesions (arrowheads).
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Figure 4.
Histogram and quartile analysis. (A) FEPro labeled 231BRL cell injected Group 1. (B)
Unlabeled cancer cell injected Group 2. Only Group 1 rats demonstrated a left shift to lower
T2* values following injection of FEPro labeled cells and significant change of the number
of voxels during the follow up studies. For rats that received unlabeled cells there was no
significant differences in the distribution of mean T2* values for the 3 weeks following IC
injection of cells compared to baseline studies.
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Figure 5.
Mismatch on Prussian blue stain with macrophage detection. (A) T2-weighted MR image
shows multiple metastatic foci as hyperintensity (arrowheads) (B) Whole brain section from
a rat that was euthanized at week 3 shows numerous metastatic foci (open arrowheads).
Hippocampal (C) and subcortical (D-F) metastatic lesions are magnified. (D) Magnified
view of a subcortical metastatic lesion (arrowheads). PB stained breast cancer cells (upper,
yellow arrowheads) and DAB stain corresponds anti CD68 for macrophage detection (lower,
black arrowheads). (C, E-F) Mismatched staining between PB positive cell (upper, yellow
arrowheads) and CD68 positive macrophage (lower, black arrowheads). Co-option of
vessels by the breast cancer cells can also be appreciated.
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Figure 6.
Cytokeratin positive breast cancer cell (left, black arrowhead) and corresponding Prussian
blue positive cells (right, yellow arrowhead) in same location. These results suggest the
possibility of dormant cancer cells at the periphery of the tumor.
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